Lipoprotein lipase and obesity

Abstract

Obesity is one of the\rfast-growing major diseases in developed and developing countries. As has\rbeen persuasively argued, long-term imbalance between intake and expenditure of\rfat is a central factor in the etiology of obesity. Obesity aggravates insulin\rresistance and promotes cardiovascular diseases and atherosclerosis. We\rhypothesized that elevating lipoprOtein lipase (LPL) activity in skeletal\rmuscle would cause an improvement of obesity. To test this hypothesis, we\rstudied the effects of the LPL activator NO-1886\r inobese animals. NO-1886 elevated LPL activity in skeletal\rmuscle, and improved obesity as well as insulin resistance in obese rats.\rFurthermore, NO-1886 mitigated body weight gain induced by pioglitazone\rwithout suppressive effect on the adiponectin-increasing action of\rpioglitazone. LPL activators hold a lot of promise of curing several diseases\rshown above in clinical scene.